Cenegermin is under clinical development by Dompe Farmaceutici and currently in Phase III for Sicca Syndrome (Sjogren). According to GlobalData, Phase III drugs for Sicca Syndrome (Sjogren) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cenegermin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cenegermin overview
Cenegermin (Oxervate) is a recombinant human nerve growth factor (rhNGF). It is formulated as drops-solution for ophthalmic and intravitreal route of administration. Cenegermin is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
Cenegermin is under development for the treatment of severe Sjogren’s dry eye disease, open-angle glaucoma and retinitis pigmentosa (U.S. and EU), back of the eye disease and severe (corneal ulcer) neurotrophic keratitis.
Dompe Farmaceutici overview
Dompe Farmaceutici (Dompe) is a biopharmaceutical company that includes research and development of innovative solutions. The company product pipeline includes ophtha – NGF, NETosis – reparixin, NETosis – ladarixin and primary care – KLS-gaba. Its products treat neurotrophic keratitis, sjogren-related dry eye, back-of-the-eye, community-acquired pneumonia (CAP), acute respiratory distress syndrome (ARDS), type 1 diabetes – early onset and insulin resistant. Dompe offers its product in therapeutic areas such as pain and anti-inflammatory, cough and cold, eye, skin, oral care and cardiovascular gastro. The company has operations in the US and China. Dompe is headquartered in Milan, Italy.
For a complete picture of Cenegermin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
